Here's why the Medlab (ASX:MDC) share price is rising today

The Medlab Clinical Ltd (ASX: MDC) share price is treading upwards today after announcing an agreement Arrotex. Here's what you need to know.

| More on:
high share price

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Medlab Clinical Ltd (ASX: MDC) share price is on the rise in mid-afternoon trade. This comes after the company announced an agreement with Australia's largest generic and over the counter pharmaceutical company, Arrotex.

Consequently, at the time of writing, the Medlab share price is fetching 34 cents apiece, up 3.08%.

Below, we take a closer look at the deal between Medlab and Arrotex.

Milestone agreement

Medlab shares are in the green today after reporting an important agreement that will unlock new opportunities for the company.

According to its release, Medlab advised it has entered an exclusive non-binding Heads of Agreement (HoA) with Arrotex.

Under the deal, Arrotex will assist Medlab in accelerating its cannabinoid formulation NanoCBD for development and distribution to Australian pharmacies. This will include fast-tracking its final application with the Therapeutic Goods Administration (TGA). Medlab hopes to position NanoCBD for pharmacist only medicines schedule (S3).

Interestingly, the HoA is the first time a pharma and biotech have formed a partnership to explore medical cannabis prospects in Australia.

The contract, which will include commercial terms, is expected to be finalised before 1 July 2021.

What did management say?

Medlab CEO Dr. Sean Hall hailed the new agreement, saying:

This is a major milestone for both the Australian market and the budding partnership between Medlab and Arrotex. Unlike many CBD producers, Medlab can deliver to the pharmaceutical standards required for TGA approval and this partnership will now enable direct application into clinical practice through Arrotex's extensive network. There is a clear alignment within both companies to deliver a superior, approved CBD product to Australian patients.

Dr. Hall went on to speak about the company's novel medicinal candidate, NanoCBD. He added:

A key differentiator of NanoCBD is the proprietary delivery platform NanoCelle that provides faster and more effective absorption of active ingredients into the bloodstream, without the need for needles or pills. It is a commercially viable platform that offer unique opportunities for partnering with some of the biggest players in the pharma industry.

How has the Medlab share price performed?

Shares in Medlab have been on a rollercoaster ride over the past 12 months, riding on volatile swings. Despite the company's shares being up a mediocre 11% since this time last year, Medlab has mostly recovered compared to its pre-COVID highs.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Fancy font saying top ten surrounded by gold leaf set against a dark background of glittering stars.
Share Gainers

Here are the top 10 ASX 200 shares today

It was another shaky day for ASX shares this Tuesday.

Read more »

forklift holding boxes next to upward trending arrow signifying share price lift
Opinions

If you don't own this ASX stalwart stock, you're missing some serious stability

This stock is riding strong tailwinds, I really like its outlook.

Read more »

ETF spelt out on cube blocks with rising arrows.
ETFs

Are these record-breaking ASX ETFs now too expensive to buy?

Should you ever buy an ETF at an all-time high?

Read more »

Two parents and two children happily eat pizza in their kitchen as a top broker predicts a 46% upside for the Domino's share price
Consumer Staples & Discretionary Shares

Buy Domino's shares for a 50% return and attractive dividend yield

Morgan Stanley believes investors should be grabbing a slice of this stock.

Read more »

Three guys in shirts and ties give the thumbs down.
Share Fallers

Why Coles, Liontown, Lovisa, and Wildcat shares are dropping today

These ASX shares are having a difficult session. But why?

Read more »

A businessman looking at his digital tablet or strategy planning in hotel conference lobby. He is happy at achieving financial goals.
Share Gainers

Why DroneShield, Healius, Newmont, and Paragon Care shares are pushing higher

These ASX shares are having a strong session on Tuesday. But why?

Read more »

a mine worker holds his phone in one hand and a tablet in the other as he stands in front of heavy machinery at a mine site.
Materials Shares

Why are ASX lithium shares like Pilbara Minerals crashing on Tuesday?

Lithium stocks are getting another whack today.

Read more »

two colleagues high five each other as they sit side by side at a long desk in front of their laptop computers in an office environment.
Mergers & Acquisitions

Guess which ASX small cap stock is rocketing 27% on 'transformative' merger

Investors are liking the look of this merger plan.

Read more »